
Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …

From Humira to Cubicin, some multi-billion dollar drugs are set to be hit hard by patent expiries next year, and …

